Literature DB >> 15077197

Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome.

Michel De Vos1, Bruce E Hayward, Susan Picton, Eamonn Sheridan, David T Bonthron.   

Abstract

We investigated a family with an autosomal recessive syndrome of cafe-au-lait patches and childhood malignancy, notably supratentorial primitive neuroectodermal tumor. There was no cancer predisposition in heterozygotes; nor was there bowel cancer in any individual. However, autozygosity mapping indicated linkage to a region of 7p22 surrounding the PMS2 mismatch-repair gene. Sequencing of genomic PCR products initially failed to identify a PMS2 mutation. Genome searches then revealed a previously unrecognized PMS2 pseudogene, corresponding to exons 9-15, within a 100-kb inverted duplication situated 600 kb centromeric from PMS2 itself. This information allowed a redesigned sequence analysis, identifying a homozygous mutation (R802X) in PMS2 exon 14. Furthermore, in the family with Turcot syndrome, in which the first inherited PMS2 mutation (R134X) was described, a further truncating mutation was identified on the other allele, in exon 13. Further whole-genome analysis shows that the complexity of PMS2 pseudogenes is greater than appreciated and may have hindered previous mutation studies. Several previously reported PMS2 polymorphisms are, in fact, pseudogene sequence variants. Although PMS2 mutations may be rare in colorectal cancer, they appear, for the most part, to behave as recessive traits. For technical reasons, their involvement in childhood cancer, particularly in primitive neuroectodermal tumor, may have been underestimated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15077197      PMCID: PMC1181988          DOI: 10.1086/420796

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  56 in total

1.  A 1.5 million-base pair inversion polymorphism in families with Williams-Beuren syndrome.

Authors:  L R Osborne; M Li; B Pober; D Chitayat; J Bodurtha; A Mandel; T Costa; T Grebe; S Cox; L C Tsui; S W Scherer
Journal:  Nat Genet       Date:  2001-11       Impact factor: 38.330

2.  The role of hPMS1 and hPMS2 in predisposing to colorectal cancer.

Authors:  T Liu; H Yan; S Kuismanen; A Percesepe; M L Bisgaard; M Pedroni; P Benatti; K W Kinzler; B Vogelstein; M Ponz de Leon; P Peltomäki; A Lindblom
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

3.  Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study.

Authors:  D Strother; D Ashley; S J Kellie; A Patel; D Jones-Wallace; S Thompson; R Heideman; E Benaim; R Krance; L Bowman; A Gajjar
Journal:  J Clin Oncol       Date:  2001-05-15       Impact factor: 44.544

4.  The interaction of the human MutL homologues in hereditary nonpolyposis colon cancer.

Authors:  S Guerrette; S Acharya; R Fishel
Journal:  J Biol Chem       Date:  1999-03-05       Impact factor: 5.157

Review 5.  The clinical and diagnostic implications of mosaicism in the neurofibromatoses.

Authors:  M Ruggieri; S M Huson
Journal:  Neurology       Date:  2001-06-12       Impact factor: 9.910

6.  The human PMS2L proteins do not interact with hMLH1, a major DNA mismatch repair protein.

Authors:  E Kondo; A Horii; S Fukushige
Journal:  J Biochem       Date:  1999-04       Impact factor: 3.387

7.  Extensive somatic microsatellite mutations in normal human tissue.

Authors:  S Vilkki; J L Tsao; A Loukola; M Pöyhönen; O Vierimaa; R Herva; L A Aaltonen; D Shibata
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

8.  Neurofibromatosis and early onset of cancers in hMLH1-deficient children.

Authors:  Q Wang; C Lasset; F Desseigne; D Frappaz; C Bergeron; C Navarro; E Ruano; A Puisieux
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

9.  Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1.

Authors:  M D Ricciardone; T Ozçelik; B Cevher; H Ozdağ; M Tuncer; A Gürgey; O Uzunalimoğlu; H Cetinkaya; A Tanyeli; E Erken; M Oztürk
Journal:  Cancer Res       Date:  1999-01-15       Impact factor: 12.701

10.  Characterization of distinct human endometrial carcinoma cell lines deficient in mismatch repair that originated from a single tumor.

Authors:  W E Glaab; J I Risinger; A Umar; T A Kunkel; J C Barrett; K R Tindall
Journal:  J Biol Chem       Date:  1998-10-09       Impact factor: 5.157

View more
  56 in total

Review 1.  Review: In vivo models for defining molecular subtypes of the primitive neuroectodermal tumor genome: current challenges and solutions.

Authors:  Jon D Larson; David A Largaespada
Journal:  In Vivo       Date:  2012 Jul-Aug       Impact factor: 2.155

2.  PMS2 mutations in childhood cancer.

Authors:  D T Bonthron; B E Hayward; M De Vos; E Sheridan
Journal:  Gut       Date:  2005-12       Impact factor: 23.059

3.  Human PMS2 gene family: origin, molecular evolution, and biological implications.

Authors:  D G Shpakovskii; E K Shematorova; G V Shpakovskii
Journal:  Dokl Biochem Biophys       Date:  2006 May-Jun       Impact factor: 0.788

Review 4.  Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations.

Authors:  Prathap Bandipalliam
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  Predictive genetic testing in children: constitutional mismatch repair deficiency cancer predisposing syndrome.

Authors:  Zandrè Bruwer; Ursula Algar; Alvera Vorster; Karen Fieggen; Alan Davidson; Paul Goldberg; Helen Wainwright; Rajkumar Ramesar
Journal:  J Genet Couns       Date:  2013-10-15       Impact factor: 2.537

6.  Efficient Detection of Copy Number Mutations in PMS2 Exons with a Close Homolog.

Authors:  Daniel S Herman; Christina Smith; Chang Liu; Cecily P Vaughn; Selvi Palaniappan; Colin C Pritchard; Brian H Shirts
Journal:  J Mol Diagn       Date:  2018-05-22       Impact factor: 5.568

7.  Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation.

Authors:  Sridharan Gururangan; Wendy Frankel; Russell Broaddus; Mark Clendenning; Leigha Senter; Marie McDonald; James Eastwood; David Reardon; James Vredenburgh; Jennifer Quinn; Henry S Friedman
Journal:  Neuro Oncol       Date:  2007-11-09       Impact factor: 12.300

8.  Case report: familial gastric cancer and chordoma in the same family.

Authors:  Walter Weber; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2005-05-15       Impact factor: 2.857

9.  Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers.

Authors:  Wenche Sjursen; Bjørn Ivar Haukanes; Eli Marie Grindedal; Harald Aarset; Astrid Stormorken; Lars F Engebretsen; Christoffer Jonsrud; Inga Bjørnevoll; Per Arne Andresen; Sarah Ariansen; Liss Anne S Lavik; Bodil Gilde; Inger Marie Bowitz-Lothe; Lovise Maehle; Pål Møller
Journal:  J Med Genet       Date:  2010-06-28       Impact factor: 6.318

10.  Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum.

Authors:  Rein P Stulp; Johanna C Herkert; Arend Karrenbeld; Bart Mol; Yvonne J Vos; Rolf H Sijmons
Journal:  Hered Cancer Clin Pract       Date:  2008-02-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.